FREMONT, Calif., July 18, 2014 /PRNewswire/ -- WaferGen
Bio-systems, Inc. (OTCBB: WGBSD) today announced that its Board of
Directors has appointed Ivan
Trifunovich, the company's President and Chief Executive
Officer, as Chairman of the Board. Joel Kanter, a director of the company since
2007, will serve as lead independent director. Alnoor Shivji, the company's Chairman since
2002, resigned from the board to focus full time on a new startup
venture.
"I would like to thank Alnoor for his service to WaferGen while
it grew from a start-up to a public company with commercially
viable products. Speaking for the whole Board, I wish him
success in his future endeavors," commented Ivan Trifunovich, President and Chief Executive
Officer.
About WaferGen
WaferGen Bio-systems, Inc. is a life science and diagnostics
company that offers innovative genomic solutions for clinical
testing and research. The SmartChip MyDesign™ Real-Time PCR System
is a high-throughput genetic analysis platform for profiling and
validating molecular biomarkers via microRNA and mRNA gene
expression profiling, as well as single nucleotide polymorphism
(SNP) genotyping. The SmartChip TE™ System is a novel product
offering for target enrichment geared towards clinical Next-Gen
sequencing (NGS). The Company now also offers the Apollo 324™
product line used in library preparation for NGS. These three
complementary technologies offer a powerful set of tools enabling
more accurate, faster and cheaper genetic analysis based on
Next-Gen Sequencing and Real-Time PCR.
For additional information, please see
http://www.wafergen.com.
Forward Looking Statements
Certain statements made in this press release contain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities and Exchange Act of 1934, as amended that are intended
to be covered by the "safe harbor" created by those sections.
Forward-looking statements, which are based on certain assumptions
and describe our future plans, strategies and expectations, can
generally be identified by the use of forward-looking terms such as
"believe," "expect," "may," "will," "should," "could," "seek,"
"intend," "plan," "estimate," "anticipate" or other comparable
terms. Forward-looking statements in this press release may address
the following subjects among others: statements regarding the
sufficiency of our capital resources, expected operating losses,
expected revenues, expected expenses, expected cash usage and our
expectations concerning our competitive position and business
strategy. Forward-looking statements involve inherent risks and
uncertainties which could cause actual results to differ materially
from those in the forward-looking statements, as a result of
various factors including those risks and uncertainties described
in the Risk Factors and in Management's Discussion and Analysis of
Financial Condition and Results of Operations sections of our most
recently filed Annual Report on Form 10-K and our subsequently
filed Quarterly Reports on Form 10-Q. We urge you to consider those
risks and uncertainties in evaluating our forward-looking
statements. We caution readers not to place undue reliance upon any
such forward-looking statements, which speak only as of the date
made. Except as otherwise required by the federal securities laws,
we disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
Investor Contacts:
ICR, Inc.
Bob Yedid
bob.yedid@icrinc.com
646-277-1250
Proactive Capital
Jeff
Ramson
jramson@proactivecrg.com
646-863-6893
WaferGen Bio-systems, Inc.
Stephen Baker
Stephen.baker@wafergen.com
510-780-2399
SOURCE WaferGen Bio-systems, Inc.